Clinical Trial Update: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of axicabtagene ciloleucel and glofitamab as second-line therapy for relapsed or refractory diffuse large…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Columvi (glofitamab) (glofitamab)
• Yescarta (axicabtagene ciloleucel) (axicabtagene ciloleucel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: B Cell Lymphoma | Phase 2 | Status: RECRUITING